# Ensysce Biosciences Inc.

Ensysce Biosciences Inc. is an Asset Manager based in San Diego, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Diego, United States
- **Region:** North America
- **Address:** 7946 Ivanhoe Avenue, Suite 201, La Jolla, CA 92037, United States
- **Assets under management:** Undisclosed
- **Website:** www.ensysce.com

## Regulatory record

- **Reports private funds:** No

## About

The company was founded in the early 2000s but no founding principals are publicly named. Ensysce operates as a publicly traded entity — shares listed on NASDAQ under ticker ENSC — and its primary focus is developing a pipeline of abuse-deterrent opioid candidates. Strategy centers on two platforms: TAAP, which releases an opioid only after being activated by trypsin in the gastrointestinal tract; and PF614, a prodrug that resists crushing or injecting. The lead product, PF614-MPAR, targets moderate-to-severe pain. Ensysce has no disclosed asset-class mix or fund structure; it relies on equity raises and partnerships for capital. As of 2024, Ensysce's team size has not been publicly disclosed. The company's offices are at 7946 Ivanhoe Avenue, Suite 201 in La Jolla, with no additional known locations. No adjacent vehicles like investing arms or foundations have been reported. A structural differentiator is Ensysce's use of trypsin-activated chemistry, which attempts to block opioid misuse via biochemical gating rather than physical barriers. This approach distinguishes its products from earlier abuse-deterrent formulations approved by the FDA.

## Questions

### Who runs investment decisions at Ensysce Biosciences?

Investment decisions at Ensysce are made by its board of directors and executive team. The CEO as of mid-2026 is Dr. Lynn Kirkpatrick (per company filings). The company is publicly traded, so capital allocation is overseen by management.

### What investment stages does Ensysce typically target?

Ensysce does not operate as an investment firm. It raises capital through public offerings and private placements to fund clinical trials. The company has not disclosed a stage-based allocation strategy.

### How does Ensysce source proprietary deal flow?

Ensysce develops its own drug candidates internally. The company does not invest in external businesses. Its pipeline originates from its in-house research and academic partnerships.

### Which sectors does Ensysce explicitly avoid?

As a publicly traded biopharmaceutical company focused on pain management, Ensysce does not invest in other sectors. It avoids areas outside of drug development for therapeutic use.

## Related profiles

- [IHS](https://altss.com/profile/ihs)
- [Data Elite](https://altss.com/profile/data-elite)

---

Updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/ensysce-biosciences-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology